The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

The maestro has appeared more frail since 2022, canceling scheduled performances that included a new production of Wagner's ...

Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, ...

The renowned musician says he plans to keep playing, after confirming the long-suspected diagnosis.

The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...

We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...

She was happily married, pregnant with her first child and had recently completed her residency in family medicine. Soon ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Ozzy Osbourne has been battling a rare form of Parkinson's Disease known as Parkin 2. In 2020, he disclosed to his fans that ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...